PL344451A1 - Use of cyclosporins in the treatment of inflammatory autoimmune diseases - Google Patents

Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Info

Publication number
PL344451A1
PL344451A1 PL99344451A PL34445199A PL344451A1 PL 344451 A1 PL344451 A1 PL 344451A1 PL 99344451 A PL99344451 A PL 99344451A PL 34445199 A PL34445199 A PL 34445199A PL 344451 A1 PL344451 A1 PL 344451A1
Authority
PL
Poland
Prior art keywords
cyclosporins
treatment
autoimmune diseases
inflammatory autoimmune
inflammatory
Prior art date
Application number
PL99344451A
Other languages
English (en)
Inventor
Peter Hiestand
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL344451A1 publication Critical patent/PL344451A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL99344451A 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases PL344451A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9811854.0A GB9811854D0 (en) 1998-06-02 1998-06-02 Organic compounds
PCT/EP1999/003770 WO1999062540A1 (en) 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Publications (1)

Publication Number Publication Date
PL344451A1 true PL344451A1 (en) 2001-11-05

Family

ID=10833083

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99344451A PL344451A1 (en) 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Country Status (17)

Country Link
EP (1) EP1082130A1 (zh)
JP (2) JP4523154B2 (zh)
KR (1) KR20010043969A (zh)
CN (1) CN1304315A (zh)
AU (1) AU750422B2 (zh)
BR (1) BR9910860A (zh)
CA (1) CA2333315A1 (zh)
GB (1) GB9811854D0 (zh)
HU (1) HUP0102142A3 (zh)
ID (1) ID27576A (zh)
IL (1) IL139589A0 (zh)
NO (1) NO20006113L (zh)
PL (1) PL344451A1 (zh)
SK (1) SK18142000A3 (zh)
TW (2) TWI250022B (zh)
WO (1) WO1999062540A1 (zh)
ZA (1) ZA200006464B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030379A2 (en) 1999-10-27 2001-05-03 Alexandra Lucas Compositions and methods for preventing and treating transplant rejection
US7419670B2 (en) * 2000-09-29 2008-09-02 Viron Therapeutics, Inc. Method of treating arthritis with SERP-1 and an immunosuppressant
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
BRPI0509690A (pt) * 2004-04-08 2007-10-09 Novartis Ag nim811 na isquemia cerebral e danos cerebrais e na medula espinhal
ATE497775T1 (de) 2004-07-14 2011-02-15 Novartis Pharma Gmbh Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
UA88484C2 (ru) * 2004-10-01 2009-10-26 Дебиофарм Са ПРИМЕНЕНИЕ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИНА ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИИ ГЕПАТИТА С И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ВКЛЮЧАЕТ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИН
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
KR20070087624A (ko) 2004-12-23 2007-08-28 노파르티스 아게 Ｈｃｖ 치료용 조성물
KR20070089954A (ko) * 2004-12-23 2007-09-04 노파르티스 아게 플라비비리대 치료용 화합물
AR054778A1 (es) 2005-06-17 2007-07-18 Novartis Ag Uso de sangliferina en hcv
JP2007112775A (ja) * 2005-10-24 2007-05-10 Hamamatsu Univ School Of Medicine サイトメガロウイルス感染の処置におけるシクロスポリン類の使用
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
JP5820722B2 (ja) * 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
CN102307892A (zh) 2008-12-31 2012-01-04 西尼克斯公司 环孢菌素a的衍生物
US20110144005A1 (en) * 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
WO2014049540A2 (en) 2012-09-29 2014-04-03 Novartis Ag Cyclic peptides and use as medicines
EP2908841A4 (en) * 2012-10-19 2016-05-25 Scynexis Inc NEW ANTIVIRAL MACROCYCLES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69124459T3 (de) * 1990-11-02 2001-05-31 Novartis Ag, Basel Zyklosporine
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
AR006514A1 (es) * 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
CZ288631B6 (cs) * 1996-01-18 2001-08-15 Galena, A. S. Léčivé přípravky s obsahem cyklosporinu
CZ288739B6 (cs) * 1996-08-01 2001-08-15 Galena, A. S. Cyklosporin obsahující léčivé přípravky

Also Published As

Publication number Publication date
TWI250021B (en) 2006-03-01
SK18142000A3 (sk) 2001-06-11
IL139589A0 (en) 2002-02-10
EP1082130A1 (en) 2001-03-14
TWI250022B (en) 2006-03-01
WO1999062540A1 (en) 1999-12-09
AU4372499A (en) 1999-12-20
CN1304315A (zh) 2001-07-18
ZA200006464B (en) 2002-03-11
ID27576A (id) 2001-04-12
GB9811854D0 (en) 1998-07-29
CA2333315A1 (en) 1999-12-09
JP2010059177A (ja) 2010-03-18
KR20010043969A (ko) 2001-05-25
NO20006113D0 (no) 2000-12-01
TW200522975A (en) 2005-07-16
HUP0102142A2 (hu) 2001-11-28
BR9910860A (pt) 2001-03-06
AU750422B2 (en) 2002-07-18
JP4523154B2 (ja) 2010-08-11
JP2002516873A (ja) 2002-06-11
NO20006113L (no) 2001-01-25
HUP0102142A3 (en) 2001-12-28

Similar Documents

Publication Publication Date Title
ZA983452B (en) Substituted pyrrolopyridines useful in the treatment of inflammatory diseases.
IL132318A0 (en) Substituted imidazoles useful in the treatment of inflammatory diseases
PL348059A1 (en) Compounds useful in the treatment of inflammatory diseases
IL133766A0 (en) 2-substituted imidazoles useful in the treatment of inflammatory diseases
PL344451A1 (en) Use of cyclosporins in the treatment of inflammatory autoimmune diseases
PL362984A1 (en) Compounds useful in the treatment of inflammatory diseases
IL144981A0 (en) Treatment of autoimmune disease
IL131025A0 (en) Treatment of autoimmune disease using tolerization in combination with methotrexate
IL148401A0 (en) Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
HK1038601A1 (en) Human body cleaner.
HK1026096A1 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
PL362350A1 (en) Chemokine mutants in the treatment of multiple sclerosis
HK1025954A1 (en) Triptolide derivatives useful in the treatment of autoimmune diseases
EP1079764A4 (en) TREATMENT OF SEXUALITY DISORDERS IN CERTAIN GROUPS OF PATIENTS
GB9927757D0 (en) Treatment of autoimmune diseases
IL129460A0 (en) Use of lofexidine in the treatment of behavioral disorders
HUP0200354A3 (en) Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
HUP0200552A2 (en) Use of apoptosis inducing agents in the treatment of (auto)immune diseases
IL140825A0 (en) Peptides for use in immunotherapy of autoimmune diseases
GB9603657D0 (en) Improvements in the treatment of vaginal infections
SI0983275T1 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
AU2002300624A1 (en) Substituted imidazoles useful in the treatment of inflammatory diseases
SI0966447T1 (en) Small molecules useful in the treatment of inflammatory disease
SI1011649T1 (en) Use of endipalene in the treatment of psoriasis
ZA978363B (en) Use of proteins as agents against autoimmune diseases.

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)